First information on the clinical activity of MK-0457 in patients with T315I and/or failure to respond to Dasatinib was presented by Dr Frank Giles at ASCO in Atlanta last week. He will update these results at EHA in Amsterdam next weekend. Many new sites in the USA and Europe will be opening within the next few weeks.
--~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---
